Background {#Sec1}
==========

For years, the quality-assured malaria diagnosis has been emphasized to effectively control malaria cases and reduce excess costs due to misdiagnosis \[[@CR1]--[@CR4]\]. With the development of malaria control interventions and the shift towards malaria elimination globally, many countries face the new challenge of increasing imported cases due to the growing human migration and travel to the malaria-endemic region \[[@CR5]--[@CR7]\]. Failing to identify and track malaria cases promptly may hinder the realization of disease elimination and impose a substantial financial burden given the higher treatment costs and public spending. This arouses a wide concern among policymakers regarding how available malaria diagnostic methods can achieve the goal of the disease control and elimination, and whether existing packages of feasible interventions can be sustainably affordable \[[@CR8]\].

So far, a remarkable improvement in the malaria diagnosis has been observed. Several malaria diagnostic methods are available for policymakers to choose: presumptive diagnosis, blood smear microscopy, polymerase chain reaction (PCR), and rapid diagnostic test (RDT) \[[@CR9]\]. The presumptive diagnosis of malaria is a conventional approach that diagnoses patients based on their symptoms and clinical signs and it is still widely adopted \[[@CR10]\]. However, it has been acknowledged that the method may add to the difficulty in effectively and accurately diagnosing the disease, and lead to a high proportion of misdiagnosis and overuse of drugs. Blood smear microscopy has advantages in both accuracy and ability to quantify parasites if it could be used properly \[[@CR11]\]. But it has high requirements for technicians' skills and experience, which is difficult to guarantee especially in low transmission sites \[[@CR12]\]. It also takes a longer time to operate, far from current expectations of an accurate and timely technique for routine malaria detection \[[@CR13]\]. PCR is appealing for its high diagnostic accuracy. On the other side, it is most costly and has high requirements on devices, materials, and technicians, making it inappropriate for countries with limited resources \[[@CR14]--[@CR16]\].

Rapid diagnostic test (RDT) is a quick diagnostic approach to detect malaria among malaria-suspected patients and rule out malaria among individuals without malaria. It has been found that the test is highly sensitive and specific \[[@CR17]\]. Meanwhile, RDT is easy to perform, and the results can be read in 15--30 min. These make it suitable for community-level health facilitates in rural areas and other endemic situations where equipment and professional microscopists are not accessible.

Given the rapid development of malaria diagnosis, enhanced case identification is operationally feasible but now the question of concern for countries embarking on malaria control and elimination is how to allocate limited resources to strengthen their current surveillance system, maintain their success and avoid the risk of re-introduction of malaria particularly when the cost is largely unknown \[[@CR18]\]. Economic evaluations can provide evidence for policymakers to identify the diagnostic test that is cost-effective and can be sustainably applied. Few studies have been carried out to evaluate the economic value of RDT, although economic evidence is necessary, and no systematic review has been performed. This study focuses on both the costs and effects of RDT and systematically evaluates whether using RDT can be cost-effective compared with other malaria diagnostic methods based on available evidence.

Methods {#Sec2}
=======

Selection criteria {#Sec3}
------------------

To assess the cost-effectiveness (cost-utility or cost-benefit), we only considered full economic evaluations that compared RDT with other common malaria diagnostic tools. A full economic evaluation should consist of two parts, i.e. costs and effects, and provide resource use, estimates of inputs and consequences for intervention. Studies were excluded if they did not use microscopy or PCR as the reference for malaria diagnosis.

Search strategy {#Sec4}
---------------

The search was performed initially in March 2017 and updated in July 2018 in the following databases: Cochrane Library, MEDLINE, EMBASE, Web of Science and Biosis Previews. We determined our search strategy with reference to previous relevant studies and systematic reviews. It was segmented into three components: malaria, malaria diagnosis techniques, and economic evaluations. To maintain the search comprehensiveness, the search was restricted to articles with the following terms in their titles, abstracts and keywords: "malaria", and "RDT", or "rapid diagnosis test", and "cost-effectiveness", "cost-effectiveness analysis", "cost-benefit analysis", "cost-utility analysis", "economic evaluations", "cost(s)", or "economy". We did not set limitations on population and languages.

Selection of studies {#Sec5}
--------------------

Two reviewers independently screened the titles, abstracts, and keywords of all searched studies and excluded irrelevant studies based on selection criteria. Then duplicates were removed. Two reviewers independently read the full-text version of each study and decided whether they should be included. Disagreements on inclusion were resolved by discussion or inviting another reviewer to judge according to the same information. Studies were named by the surname of their first author and the year of publication.

Data extraction {#Sec6}
---------------

Two reviewers independently extracted data based on a well-designed data extraction table, summarized important information and made a descriptive analysis to draw a conclusion about the cost-effectiveness of RDT.

The following data were extracted: General information: first author, study year, country, the prevalence of malaria, source of funding, participants of the study, intervention and its comparisons, commercial name of RDT, the type of RDT.Methodological information: types of study (cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis), study design, study perspective, time horizon, outcome measures, discount rate, currency, price year and willingness to pay threshold.Results and conclusions: incremental costs, incremental effectiveness, incremental cost-effectiveness ratio (ICER) reported, and sensitivity analysis.

Quality assessment {#Sec7}
------------------

Strict quality assessment can reflect the methodological quality of health economics research and control risk of bias. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS, <http://www.equator-network.org/wp-content/uploads/2013/04/Revised-CHEERS-Checklist-Oct13.pdf>), a comprehensive quality assessment tool recommended by the International Society for Pharmacoeconomics and Outcomes Research, were used to examine the quality of studies. The CHEERS checklist assesses the reporting quality based on items from the following aspects: "title and abstract", "introduction", "methods", "discussion" and "other". Each item would be appraised critically in accordance with the requirements of CHEERS statements. The evaluation results were shown as 'Yes', 'No' and 'Not clear' marked as 1, 0 and 0 respectively, then the scores of the 24 items were summed up to calculate the final score of each study. Scores would be divided into three levels to identify the quality of each article: high (studies that met over 75% items or scored between 19 and 24), moderate (studies that met 50--75% items or scored between 13 and 18) and low (studies that met less than 50% items or scored 12 or lower).

Analysis methods {#Sec8}
----------------

As meta-analysis or other quantitative synthesis methods are not recommended to combine the cost-effectiveness from different economic evaluations \[[@CR19]\], we summarized results of each study in a narrative way and presented incremental costs, incremental effectiveness, and ICERs in structured tables if such information was available.

The narrative and tabular summary were structured based on the age of the population and the perspective of economic evaluations since participants' age might influence the economic results of the intervention \[[@CR20]--[@CR22]\], and the perspectives could determine the costs and effects that were included in the evaluations. We also recognized that there might be potential impact brought by the type of RDTs and funding sources on the economic values of diagnostic tests and took it into account in our analysis.

To facilitate the comparison across different studies, original costs reported were converted to a common currency and price year, 2019 United States dollars (USD), given the latest version of a web-based cost converter. This tool adjusts cost estimates based on purchasing power parity (PPP) and gross domestic product (GDP) deflator index and has been recommended by the guidelines of systematic review \[[@CR19], [@CR23]\]. ICERs were then recalculated by dividing the converted costs by the original effects. In order to graphically compare the economic value of different malaria diagnostic methods, we adopted the cost-effectiveness plane to reflect the differences in ICER, the only appropriate measure that can capture the true economic value \[[@CR24]\], for studies that provided relevant data and took the same outcomes of effectiveness. Studies would be categorized according to the perspectives of economic evaluations. We recognized that taking narrower perspectives (e.g., a provider perspective) could impede the comparability of the results throughout healthcare systems and ignore the implication of opportunity costs brought by the introduction of new technologies \[[@CR25], [@CR26]\]. Thus we selected results from studies taken the societal perspective and the same outcome measures and plotted them on the same cost-effectiveness plane.

Results {#Sec9}
=======

One thousand seven hundred forty studies were identified from electronic databases. After screening the titles, abstracts, and keywords, 1595 studies were removed based on inclusion and exclusion criteria, 85 studies were removed due to the duplicates and 60 full-text potentially eligible articles were retrieved for the consideration. Finally, 15 studies were included in the analysis \[[@CR27]--[@CR41]\]. The flow diagram of our study selection is shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Study flow diagram. Flowchart showing inclusion and exclusion process of study identification. RDT: Rapid diagnostic test

General characteristics of studies {#Sec10}
----------------------------------

We included fifteen studies that compared the economic value of RDT with other malaria diagnostic methods. Fourteen studies were full health economic evaluations that made a comparison in terms of costs and effectiveness between RDT and its comparators. All of them were cost-effectiveness analyses, nine of which used decision tree models. Besides, one study, although did not say that it was a cost-effectiveness analysis, assessed both the costs and the specificity of RDT, thus we also considered it as full economic evaluations and included it \[[@CR28]\] (Table [1](#Tab1){ref-type="table"}). Table 1General characteristics of studies includedStudy IDStudy YearCountryPrevalence of malariaStudy TypeDesignParticipantsInterventionCommercial name of RDTTypes of RDTQualityQuality classBatwala 2011 \[[@CR27]\]2010/03--2011/02UgandaHigh/LowCEADecision tree22 052 fever outpatientsmicroscopy13ModerateRDTParacheckSingleGitonga 2012 \[[@CR28]\]2008/09--2010/03KenyaStable & seasonal transmissionCost analysisCross-sectional study49 891 studentsmicroscopy7LowRDTOptiMal - ITSingleParacheck - Pf deviceSingleParacheck - Pf dipstickSingleCareStart - Pf/Pv comboComboHansen 2015 \[[@CR29]\]2009/09--2010/09AfghanistanModerate/LowCEADecision tree5749 suspected malaria patientsRDTCareStart Malaria RDT Pf/PanCombo22HighHansen 2017a \[[@CR30]\]2011/01--2011/12UgandaNot clearCEADecision tree13 319 customers suspected malaria and visiting drug shopsRDTFirst ResponseSingle15ModerateHansen 2017b \[[@CR31]\]2011/01--2011/12UgandaModerate to high/LowCEADecision treeChildren under five visiting CHWsRDTFirst ResponseSingle12LowLemma 2011 \[[@CR32]\]2007EthiopiaNot clearCEACross-sectional study2422 malaria suspected patientsRDTParacheck - pfSingle11LowParascreen - pan/pfComboLubell 2007 \[[@CR33]\]2005TanzaniaHigh/LowCEARCT2416 patients requested for a parasitological testRDTParacheck - pfSingle10LowLy 2010 \[[@CR34]\]2008/10--2009/01SenegalHigh/ModerateCEACross-sectional study189 suspected malaria patientsRDTParacheck - pfSingle12LowMatangila 2014 \[[@CR35]\]2012/07--2012/08CongoNot clearCEACross-sectional study332 pregnant womenmicroscopy18ModerateRDTSD Bioline Malaria Ag PfSingleOliveira 2010 \[[@CR36]\]2006BrazilNot clearCEADecision tree33 491 individuals with fevermicroscopy15ModerateRDTOptiMalComboOliveira 2012 \[[@CR37]\]2010Brazilian Extra-AmazonLowCEADecision tree2702 suspected patients who took the diagnostic tests in Extra-Amazon region in 2010RDT (5 brands)SD Bioline FK60 (PF/Pan)Combo11LowCareStart (Pan)First ResponseParascreenTM (Pf/Pan)ICT BinaxNOW MalariaOsei-Kwakye 2013 \[[@CR38]\]2009/01--2010/02GhanaHighCEACross-sectional study936 children under five years with fever at the outpatient departmentmicroscopy18ModerateRDTParascreenComboShillcutt 2008 \[[@CR39]\]NRSub-Saharan endemic countriesAll levelsCEADecision treeA hypothetical cohort of outpatients with fever in rural area of sub-Saharan Africamicroscopy11LowRDTa hypothetical HRP2-based RDT for *P. falciparum*SingleTawiah 2016 \[[@CR40]\]NRGhanaHighCEADecision tree100 children under 24 months per health center in total 32 health centersRDTCareStart23HighFirst ResponseSingleUzochukwu 2009 \[[@CR41]\]2005--2007NigeriaHighCEADecision tree638 patients with fever, diagnosed as malariamicroscopy11LowRDTICT Malaria Combo Cassette TestCombo*NR* Not report, *SNMCP* The Senegalese National Malaria Control Programme, *CEA* Cost-effectiveness analysis, *RCT* Randomised controlled trial, *RDT* Rapid diagnostic test, *IT* Individual test, *Pf* *Plasmodium falciparum*, *Pv* *Plasmodium vivax*, *CHW* Community health workersQuality: the reporting quality of each study identified based on CHEERS checklist with a maximum score of 24. Quality class: quality rating was divided into three categories based on scores: high (19--24), moderate (13--18) and low (0--12)

Most of the studies were conducted in Africa, except three: one in Afghanistan \[[@CR29]\], and two in Brazil \[[@CR36], [@CR37]\]. The Africa-based studies were all performed in Sub-Saharan Africa (Ethiopia \[[@CR32]\], Congo \[[@CR35]\], Ghana \[[@CR38], [@CR40]\], Kenya \[[@CR28]\], Nigeria \[[@CR41]\], Senegal \[[@CR34]\], Tanzania \[[@CR33]\], Uganda \[[@CR27], [@CR30], [@CR31]\]). One study targeted at all endemic countries in Sub-Saharan Africa using a simulated cohort with fever in the rural areas \[[@CR39]\].

Eleven studies focused on suspected malaria and fever patients. Among the other four studies, two targeted at children \[[@CR38], [@CR40]\], one focused on the application of RDT in school students \[[@CR28]\], and one assessed the effectiveness of RDT among healthy pregnant women \[[@CR35]\].

Quality assessment {#Sec11}
------------------

According to the CHEERS checklist, huge gaps existed in the quality of evidence reported. Scores ranged from 7 to 23. Two studies provided a high quality of evidence with the highest score of 23 \[[@CR29], [@CR40]\], five had evidence of moderate quality \[[@CR27], [@CR30], [@CR35], [@CR36], [@CR38]\], and eight had low quality with the lowest score of 7 \[[@CR28], [@CR31]--[@CR34], [@CR37], [@CR39], [@CR41]\]. The overall quality of all studies included could be seen in Fig. [2](#Fig2){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}. Fig. 2Quality assessment results of studies includedThe quality of each included study was assessed based on the 24-item CHEERS checklist with a maximum score of 24 if the study could meet quality criteria for all the items.

The cost-effectiveness of RDT {#Sec12}
-----------------------------

The economic value of RDT was assessed in the fifteen economic evaluations and summarized in Table [2](#Tab2){ref-type="table"}. Three malaria diagnostic techniques were reported and compared in all papers: RDT, microscopy, and presumptive diagnosis, and the majority took microscopy and/or presumptive diagnosis method as the comparison for RDT. Table 2Summaries of economic results of included studiesStudy IDStudy perspectiveTime horizonEffectiveness measuresIncremental costsIncremental effectivenessICERsSensitivity analysisWillingness-to-pay thresholdPrice yearDiscount rateBatwala 2011 \[[@CR27]\]Societal12 monthsThe number and proportion of patients correctly diagnosed and treatedRDT vs presumptive: USD 1.17RDT vs presumptive: 0.234Incremental cost per patient correctly diagnosed and treated of replacing presumptive diagnosis by RDT was USD5.0; and by microscopy was USD 9.61. In high transmission setting, the ICER was USD 4.38 for RDT and was USD 12.98 for microscopy. In low transmission setting, the ICER was USD 5.85 for RDT and USD 7.63 for microscopy.Reduction in the cost of AL and RDT, and increase in malaria prevalence were associated with improvement in the cost-effectiveness of RDT.USD 2.8USD 20113%RDT vs microscopy: USD - 0.31RDT vs microscopy: 0.08Gitonga 2012 \[[@CR28]\]NRNRThe percentage of districts in a given prevalence that were correctly classifiedNRNRThe incremental analysis was not performedNRNRUSD 2008--20103%Hansen 2015 \[[@CR29]\]Societal12 monthsAppropriate treatment of suspected malariaRDT vs presumptive (low transmission): USD 2.4RDT vs presumptive (low transmission): 53.4%Incremental cost per appropriately treated patient of replacing presumptive diagnosis by RDT was USD 4.5 from a societal perspective.Probabilistic sensitivity analysis: RDT vs presumptive - Improved effects compared but uncertainty in the incremental costs. RDT vs microscopy - In moderate transmission setting, improved effects in RDT but uncertainty in the incremental costs; In low transmission setting, lower costs in RDT but uncertainty in the effects. Scenario analysis: RDT remained cost-effective compared to microscopy if chloroquine was replaced by ACT or the price of ACT increased.NRUSD 20093%RDT vs microscopy (moderate transmission): USD - 0.3 RDT vs microscopy (low transmission): USD - 7.1RDT vs microscopy (moderate transmission): 7.4% RDT vs microscopy (low transmission): 4%Incremental cost per appropriately treated patient of replacing microscopy by RDT from a societal perspective was USD - 4.1 (dominant) in moderate transmission setting and USD - 177.5 (dominant) in low transmission setting.Health sectorRDT vs presumptive (low transmission): USD 1.3RDT vs presumptive (low transmission): 53.4%Incremental cost per appropriately treated patient of replacing presumptive diagnosis by RDT was USD 2.5 from a health sector perspective.RDT vs microscopy (moderate transmission): USD - 0.0 RDT vs microscopy (low transmission): USD - 7.1RDT vs microscopy (moderate transmission): 7.4% RDT vs microscopy (low transmission): 4%Incremental cost per appropriately treated patient of replacing microscopy by RDT from a health sector perspective was USD - 0.0 (dominant) in moderate transmission setting and USD - 177.5 (dominant) in low transmission setting.Hansen 2017a \[[@CR30]\]Societal12 monthsAppropriate treatment of malaria with ACT or rectal artesunateRDT vs presumptive: USD 1658RDT vs presumptive: 433Incremental cost per additional patient appropriately treated of malaria for RDT compared to presumptive diagnosis was USD 3.83 from a societal perspectiveUnivariate sensitivity analysis: ICER was sensitive to malaria prevalence levels, RDT price, the specificity of RDT, higher popularity of drug shops offering RDT, adherence to RDT results and ACT prices. Probabilistic sensitivity analysis: Improved effects of RDT. Increased costs of RDT from a health sector perspective and uncertainty in incremental costs from a societal perspectiveNRUSD 20113%Health sectorRDT vs presumptive: USD 239Incremental cost per \` patient appropriately treated of malaria was USD 0.55 from a health sector perspectiveHansen 2017b \[[@CR31]\]Societal12 monthsAppropriate treatment of malaria with ACTRDT vs presumptive (moderate to high transmission): USD 1755RDT vs presumptive (moderate to high transmission): 485In moderate-to-high transmission setting, incremental cost per additional appropriately treated child under five from a societal perspective was USD 3.6.Univariate sensitivity analysis: ICER was sensitive to malaria prevalence levels, RDT price, adherence to RDT results and the number of children visiting community health workers. Probabilistic sensitivity analysis: Improved effects of RDT but also increased costsNRUSD 20113%RDT vs presumptive (low transmission): USD 12283RDT vs presumptive (low transmission): 822In low transmission setting, incremental cost per additional appropriately treated child under five from a societal perspective was USD 14.9.Health sectorRDT vs presumptive (moderate to high transmission): USD 1462RDT vs presumptive (moderate to high transmission): 485In moderate-to-high transmission setting, incremental cost per additional appropriately treated child under five from a health sector perspective was USD 3.0.RDT vs presumptive (low transmission): USD 10924RDT vs presumptive (low transmission): 822In low transmission setting, incremental cost per additional appropriately treated child under five from a health sector perspective was USD 13.3.Lemma 2011 \[[@CR32]\]ProviderNRThe number of correctly treated casesRDT (Parascreen) vs presumptive: USD - 1388.44RDT (Parascreen) vs presumptive: 1690Incremental cost on Parascreen-BS over presumptive was USD - 0.82Result robust: presumptive diagnosis was always dominated.NRUSD 2007NRRDT (Paracheck) vs presumptive: USD - 2312.71RDT (Paracheck) vs presumptive: 127Incremental cost on Paracheck-BS over presumptive was USD - 18.21Lubell 2007 \[[@CR33]\]ProviderNRThe proportion of patients correctly treatedRDT vs microscopy (high transmission): USD 0.6RDT vs microscopy (high transmission): 9.4%In high transmission setting, incremental cost per additional patient correctly treated was USD 7.0ICER was sensitive to malaria prevalence and the price of RDT. Result was robust to the cost of ACT.NRUSD 2005NRRDT vs microscopy (low transmission): USD 0.6RDT vs microscopy (low transmission): 2.3%In low transmission setting, incremental cost per additional patient correctly treated was USD 25.2Ly 2010 \[[@CR34]\]SNMCPNRThe proportion of patients would have been correctly managedTreatment of all RDT positive patients vs presumptive treatment of all the febrile patients based on their body temperature: \$ 460.16 (€ 336.3) per 1000 episodesTreatment of all RDT positive patients vs presumptive treatment of all the febrile patients based on their body temperature: 48.1%Incremental cost per additional episode of illness correctly managed of treatment of all RDT positive patients compared to presumptive treatment of all the febrile patients based on their body temperature was \$ 0.96 (€ 0.699)The cost would increase around 50% with full adherence to the test results.NREUR2008--2009NRTreatment of all RDT positive patients vs presumptive treatment of suspected patients based on health care provider's feeling: \$ 448.12 (€ 327.5) per 1000 episodesTreatment of all RDT positive patients vs presumptive treatment of suspected patients based on health care provider's feeling: 46.6%Incremental cost per additional episode of illness correctly managed of treatment of all RDT positive patients compared to presumptive treatment of suspected patients based on health care provider's feeling was \$ 0.96 (€ 0.703)Treatment of all RDT positive patients vs treatment of all febrile RDT positive patients: \$ 484.10 (€ 353.8) per 1000 episodesTreatment of all RDT positive patients vs treatment of all febrile RDT positive patients: 2.6%Incremental cost per additional episode of illness correctly managed of treatment of all RDT positive patients compared to treatment of all febrile RDT positive patients was \$ 18.62 (€ 13.608)Treatment of all RDT positive patients vs treatment of all children under 6 and all RDT positive patients above 6:\$ 119.73 (€ 87.5) per 1000 episodesTreatment of all RDT positive patients vs treatment of all children under 6 and all RDT positive patients above 6:40.2%Incremental cost per additional episode of illness correctly managed of treatment of all RDT positive patients compared to treatment of all children under 6 and all RDT positive patients above 6 was \$ 0.30 (€ 0.218)Matangila 2014 \[[@CR35]\]Provider1 monthThe number of cases correctly diagnosedRDT vs microscopy: USD - 1.46RDT vs microscopy: 2.3%Incremental cost per additional case correctly diagnosed for RDT compared to microscopy was USD - 63.47.Sensitivity analysis for the incremental analysis was not performed.NRUSD 2012NROliveira 2010 \[[@CR36]\]Public health system12 monthsThe number of adequate diagnosis of suspected malariaRDT vs microscopy: USD -1.65RDT vs microscopy: - 0.3%Incremental cost per additional case correctly diagnosed for RDT compared to microscopy was USD 549.92ICER was sensitive to the sensitivity and specificity of microscopy, the specificity of RDT, the cost of RDT, the cost of transportation to perform one rapid test and thick smear.NRUSD 20065%Oliveira 2012 \[[@CR37]\]Public health system12 monthsAdequately diagnosed cases of malariaRDT (First Response malaria combo) vs exclusive-use microscopy: USD - 24.37RDT (First Response malaria combo) vs exclusive-use microscopy: - 0.0685Incremental cost per additional adequately diagnosed by First Response Malaria Combo compared to exclusive-use microscopy was USD 355.77ICERs of ICT BinaxNOW and CareStart in relation to both exlusive- and shared-use microscopy were robust to the cost of RDT. The cost-effectiveness of SD Bioline was sensitive to the malaria prevalence when RDTs were compared with exclusive-use microscopy. The cost-effectiveness of shared-use microscopy was sensitive to the sensitivity to P.vivax of microscopy and RDT.NRUSD 2010NRRDT (Parascreen) vs exclusive-use microscopy: USD - 24.27RDT (Parascreen) vs exclusive-use microscopy: - 0.1141Incremental cost per additional adequately diagnosed by Parascreen compared to exclusive-use microscopy was USD 212.71RDT (SD Bioline FK60) vs exclusive-use microscopy: USD - 24.26RDT (SD Bioline FK60) vs exclusive-use microscopy: - 0.0767Incremental cost per additional adequately diagnosed by SD Bioline FK60 compared to exclusive-use microscopy was USD 316.30RDT (CareStart) vs exclusive-use microscopy: USD - 21.33RDT (CareStart) vs exclusive-use microscopy: - 0.0006Incremental cost per additional adequately diagnosed by CareStart compared to exclusive-use microscopy was USD 35550RDT (ICT BinaxNOW) vs exclusive-use microscopy: USD - 20.26RDT (ICT BinaxNOW) vs exclusive-use microscopy: - 0.0369Incremental cost per additional adequately diagnosed by ICT BinaxNOW compared to exclusive-use microscopy was USD 549.05RDT (First Response malaria combo) vs shared-use microscopy: USD - 0.55RDT (First Response malaria combo) vs shared-use microscopy: - 0.0685Incremental cost per additional adequately diagnosed by First Response Malaria Combo compared to shared-use microscopy was USD 8.03RDT (Parascreen) vs shared-use microscopy: USD - 0.45RDT (Parascreen) vs shared-use microscopy: - 0.1141Incremental cost per additional adequately diagnosed by Parascreen compared to shared-use microscopy was USD 3.94RDT (SD Bioline FK60) vs shared-use microscopy: USD - 0.44RDT (SD Bioline FK60) vs shared-use microscopy: - 0.0767Incremental cost per additional adequately diagnosed by SD Bioline FK60 compared to shared-use microscopy was USD 5.74RDT (CareStart) vs shared-use microscopy:USD 2.49RDT (CareStart) vs shared-use microscopy:- 0.0006Incremental cost per additional adequately diagnosed by CareStart compared to shared-use microscopy was USD - 4150RDT (ICT BinaxNOW) vs shared-use microscopy: USD 3.56RDT (ICT BinaxNOW) vs shared-use microscopy: - 0.0369Incremental cost per additional adequately diagnosed by ICT BinaxNOW compared to shared-use microscopy was USD - 96.48Osei-Kwakye 2013 \[[@CR38]\]Patient12 monthsThe number of cases correctly diagnosedRDT vs presumptive: USD 1.00NRThe incremental analysis was not performed.Sensitivity analysis for the incremental analysis was not performed.NRNRRDT vs microscopy: USD - 1.50NRShillcutt 2008 \[[@CR39]\]Provider and patientNRDALYs avertedNRNRNRRDT was constantly more cost-effective compared to microscopy and the cost-effectiveness of RDT compared to presumptive diagnosis was sensitive to malaria prevalence, ACT cost, adherence to antibiotics, whether the illness was bacterial, whether a patient diagnosed as not having malaria received antibiotics and policy-maker's willingness to pay.USD 150USD 2002NRTawiah 2016 \[[@CR40]\]Societal2 yearsThe number of appropriately treated childrenRDT vs presumptive: USD 1474 per 1000 fever episodesRDT vs presumptive: 134 per 1000 fever episodesIncremental cost of introducing RDT to replace presumptive diagnosis per additional appropriately treated child under five from a societal perspective was USD 11.0Univariate sensitivity analysis: ICERs from health sector and societal perspective were sensitive to adherence to RDT results, malaria prevalence, RDT specificity. Bivariate sensitivity analysis: ICER was insensitive to the accuracy of RDT. Probabilistic sensitivity analysis: Always improved effects but an increase in costs from a health sector perspective and uncertainty in costs from a societal perspective.NRUSD 20115%Health sectorRDT vs presumptive: USD 2492 per 1000 fever episodesIncremental cost of introducing RDT to replace presumptive diagnosis per additional appropriately treated child under five from a health sector perspective was USD 18.6.Uzochukwu 2009 \[[@CR41]\]Provider and patientNRDeaths averted based on the use of the alternative diagnostic strategiesRDT vs presumptive: USD -27 960 per 100 000 malaria casesRDT vs presumptive: 127 per 100 000 malaria casesIncremental cost of introducing RDT to replace presumptive diagnosis per death averted was USD - 221.ICER was sensitive to malaria prevalence, the proportion of non-malaria febrile episodes that were bacterial, sensitivity of RDT, adherence to ACT, the cost of RCT and the cost of ACT.NRUSD 2008NRRDT vs microscopy: USD -56 781 per 100 000 malaria casesRDT vs microscopy: 11 per 100 000 malaria casesIncremental cost of introducing RDT to replace microscopy per death averted was USD - 5162.*NR* Not report, *SNMCP* The Senegalese National Malaria Control Programme, *AL* Artemether-lumefantrine, *ACT* Artemisinin-based combination therapy, *RDT* Rapid diagnostic test, *ICER* Incremental cost-effectiveness ratio; *DALY* Disability-adjusted life year

RDT vs microscopy {#Sec13}
-----------------

Microscopy is a conventional diagnostic method to detect malaria infection. Six out of fifteen studies found that introducing RDT to substitute microscopy was likely to be cost-effective \[[@CR27], [@CR29], [@CR35], [@CR37], [@CR39], [@CR41]\]. Four of them made that conclusion as RDT could lead to either lower costs and improved outcomes, or a cost-saving when compared to microscopy \[[@CR29], [@CR35], [@CR37], [@CR41]\]. A cost-effectiveness analysis based on decision tree compared RDT and microscopy to presumptive diagnosis simultaneously \[[@CR27]\]. It found that overall, RDT had lower positive ICER than microscopy and was most cost-effective in both high and low transmission settings. A decision-analytical study presented evidence of the cost-effectiveness of RDT compared to both microscopy and presumptive diagnosis \[[@CR39]\]. With a threshold of USD 150 for the incremental cost per addition averted disability-adjusted life years (DALYs), RDT was highly likely to be cost-effective.

RDT vs presumptive diagnosis {#Sec14}
----------------------------

The cost-effectiveness of RDT in comparison to the presumptive diagnostic method was reported in ten studies, and all of them used presumptive diagnosis as a base case with RDT as the intervention to compare \[[@CR27], [@CR29]--[@CR32], [@CR34], [@CR38]--[@CR41]\]. Eight studies provided supportive evidence that RDT was highly likely to be cost-effective: three studies observed that the use of RDT could be less costly while more effective \[[@CR27], [@CR32], [@CR41]\], three studies found that RDT could result in an increase in both costs and effectiveness but it had the potential to be cost-effective at a low willingness to pay (WTP) threshold \[[@CR29], [@CR30], [@CR40]\], another study observed a low ICER of RDT but admitted that whether RDT could be cost-effective would depend on how much decision-makers would be willing to pay \[[@CR31]\], and a decision-based analysis showed that RDT was 85% certain to be cost-effective at all prevalence level below 65% \[[@CR39]\].

Perspectives {#Sec15}
------------

Studies took a wide range of study perspectives which determined the scope of costs and effects within the evaluations: five studies were conducted from the societal perspective, four adopted a perspective of the health sector, one study did not report its perspective and the rest were undertaken under narrower perspectives such as provider or patient. There was a high level of heterogeneity among the selection of outcome measures among studies with narrow perspectives while the five studies under a societal perspective adopted either the number or the proportion of appropriately treated patients as the outcome, which can be considered as the same measure of effectiveness. We thus would take "the number of appropriately treated per 1000 suspected cases" as the main outcome and recalculate the results based on the available data.

The comparison of the economic value of RDT between five studies taking a societal perspective was plotted in Fig. [3](#Fig3){ref-type="fig"}. Compared with other diagnostic techniques, the incremental effects of RDT were always positive, i.e., using RDT could contribute to an increase in the number of appropriately treated patients, but its impact on additional societal costs was not clear and could largely depend on the comparator selected. The introduction of RDT to replace presumptive diagnosis resulted in an increase in costs \[[@CR27], [@CR29]--[@CR31], [@CR40]\], but that increase was relatively small in most of the studies. There were two studies that provided evidence for the comparison between RDT and microscopy from a societal perspective, they observed a cost-saving effect when RDT was introduced \[[@CR27], [@CR29]\]. Overall, given a small number of studies, it could be found that RDT had the potential to be cost-effective particularly compared to microscopy under a societal perspective and whether RDT could be a dominant strategy would largely depend on the threshold of policymakers. Fig. 3Incremental cost-effectiveness ratio of studies included (societal perspective)Each point represents differences in the costs and effectiveness between RDT and its alternatives from included studies under a societal perspective.RDT: Rapid diagnostic test.

Similar trends could be observed when economic evaluations were undertaken under a health sector perspective. Most of them concluded that RDT was cost-effective when it was compared to microscopy and likely to be cost-effective when compared with the presumptive diagnosis. RDT can keep its advantages over microscopy with lower costs and more patients appropriately treated \[[@CR29], [@CR31], [@CR40]\]. It can also largely improve the clinical performance but resulted in a slight increase in the health sector costs if it was used to replace presumptive diagnosis \[[@CR29]--[@CR31], [@CR40]\]. Further details of cost-effectiveness in studies included could be seen in Additional files [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}.

Prevalence {#Sec16}
----------

Changes to the malaria prevalence tended to have an impact on the costs and effects of diagnostic methods. Thirteen studies recognized its potential influence on the cost-effectiveness of RDT compared to other methods but only eight of them formally investigated the uncertainty brought by malaria prevalence \[[@CR27], [@CR30], [@CR31], [@CR33], [@CR37], [@CR39]--[@CR41]\]. The introduction of RDT to replace microscopy was found to be a dominant strategy regardless of the prevalence levels \[[@CR27], [@CR37], [@CR39], [@CR41]\], but the ICER could be lower with an increase in prevalence \[[@CR33]\]. The cost-effectiveness of RDT against presumptive diagnosis was consistent: all the four studies that tested the robustness of the results found that RDT could be more cost-effective in the area with lower prevalence \[[@CR30], [@CR31], [@CR39], [@CR40]\].

Age {#Sec17}
---

Among all included studies, eleven had no restriction on participants' age and four limits the population to students or children of different ages. Evidence showed that whether RDT could be cost-effective compared to other diagnostic methods was not likely to be influenced by the age of the target population. Of the four papers with a limitation on the age, half applied RDT on children under 5 years old and supported the cost-effectiveness of this diagnostic method \[[@CR31], [@CR40]\], while the other half focused on children as well and did not reach that conclusion, but both of them recognized the cost-saving effect of RDT compared to microscopy \[[@CR28], [@CR38]\]. Of eleven studies without a limitation on age, eight showed that RDT could be more cost-effective compared with other methods \[[@CR27], [@CR29], [@CR30], [@CR32], [@CR35], [@CR37], [@CR39], [@CR41]\]. The majority of economic evaluations included considered RDT as a cost-effective strategy regardless of whether the study limited the subjects' age. Further details can be seen in Additional files [2](#MOESM2){ref-type="media"} and [3](#MOESM3){ref-type="media"}.

The types of RDT {#Sec18}
----------------

There are various types of RDT: some of them can detect single *Plasmodium* species, some can detect multiple species and some can distinguish between different species \[[@CR42]\]. The difference in the types may bring extra costs to the economic value of RDT as they may have different prices. To compare the impact of RDT types, we categorized RDT into two categories: one is a single test which only detects single species, another is a combo test which can detect multiple *Plasmodium* species. The types of RDT used in included studies varied greatly. Ten studies adopted single test \[[@CR27], [@CR28], [@CR30]--[@CR35], [@CR39], [@CR40]\], while combo tests were used in seven studies \[[@CR28], [@CR29], [@CR32], [@CR36]--[@CR38], [@CR41]\].

Evidence suggested that single RDT could be cost-effective compared to microscopy and presumptive diagnosis. *Plasmodium falciparum*-specific RDTs were adopted in eight studies: four of them were decision analytical economic evaluations and suggested that the introduction of single RDT tests can largely improve the proportion of appropriate treatment for patients \[[@CR27], [@CR30], [@CR31], [@CR40]\]. In the other four studies, two of them found that RDT was likely to be more cost-effective than microscopy \[[@CR35], [@CR39]\], and the remaining two studies adopted single and multiple tests at the same time. In the first study conducted in Ethiopia where *P. falciparum* and *P. vivax* co-exist, both single and multiple tests were used to appraise the cost-effectiveness of RDT compared to presumptive treatment \[[@CR32]\]. In the area with various malaria species, multiple tests were more cost-effective than either a single test or presumptive diagnosis. In a second study, a cost analysis was performed to appraise the performance of four RDT brands, including single and multiple tests, but it did not assess the effectiveness of multiple tests and only reported costs of general RDTs rather than costs by each RDT type \[[@CR28]\].

However, the cost-effectiveness of combo tests was not clear. Four of seven studies showed positive results regarding the cost-effectiveness of combo RDT. Three studies that appraised the costs and effectiveness of RDT based on decision models observed lower costs and more clinical benefits with the use of multiple tests than microscopy \[[@CR29], [@CR37], [@CR41]\]. Lemma et al. found that multiple tests performed better and cost lower than both single tests and presumptive diagnoses in the context where *P. falciparum* and *P. vivax* co-dominate \[[@CR32]\]. However, the cost-effectiveness of multiple tests applied in the remote area of Amazon where *P. falciparum* and *P. vivax* dominate as well were uncertain as it largely depended on the accessibility to and the accuracy of microscopy \[[@CR36]\]. Evidence identified in this review observed that RDT could also lead to the problem of over-diagnosis \[[@CR28], [@CR38]\]. Although RDT was the cheapest approach to detect infection in malaria school surveys compared to other strategies (i.e., microscopy or RDT corrected by alternative methods), it over-estimated the prevalence of infection \[[@CR28]\]. Also, the study only evaluated the costs of diagnosis and thus the cost-saving effect of RDT could be maintained remainsed unclear when treatment costs were taken into account. The treatment costs were found to be higher for RDT than for microscopy when *P. falciparum* and *pan*-specific RDT was used to the management of malaria cases in Ghana \[[@CR38]\]. The study also observed the over-diagnosis and additional costs when RDT was introduced to replace presumptive diagnosis. This may reduce RDT's advantage in terms of cost-effectiveness.

In general, the impact of the types of RDT on its cost-effectiveness remained uncertain given various types of RDT, the complexity of local epidemiological characteristics and the lack of evidence reported in studies included. Further details of the types and brands of RDT can be seen in Table [1](#Tab1){ref-type="table"}.

Funding sources {#Sec19}
---------------

Fourteen of all fifteen studies received funding from various sources (Additional file [4](#MOESM4){ref-type="media"}). It was not clear based on current evidence whether founding sources would have an impact on whether RDT was cost-effective. Seven studies were government-sponsored, either intergovernmental organization or local government \[[@CR28], [@CR32], [@CR34], [@CR35], [@CR37], [@CR39], [@CR41]\], and five of them supported the cost-effectiveness of RDT \[[@CR32], [@CR35], [@CR37], [@CR39], [@CR41]\]. Of eight studies that did not receive funding from the government \[[@CR27], [@CR29]--[@CR31], [@CR33], [@CR36], [@CR38], [@CR40]\], seven were sponsored by either non-governmental organizations or research institutions including universities and five studies reported that RDT was cost-effective \[[@CR27], [@CR29]--[@CR31], [@CR40]\]. There was only one study that had no statement of the source of funding, and its result did not support RDT's cost-effectiveness because it found that if the accuracy of microscopy could be guaranteed, there would be no additional benefits of applying RDT \[[@CR36]\]. As most of the studies included received funding from nonprofit organizations and there was only one research that did not report its funding source, the impact of funding sources was less clear.

Discussion {#Sec20}
==========

Economic evidence for RDT {#Sec21}
-------------------------

Our study aimed at assessing the cost-effectiveness of RDT in a systematic manner. Overall, we identified fifteen studies that tried to delve out whether RDT was cost-effective compared with other commonly used malaria diagnosis methods and there was heterogeneity in population age, funding sources, economic and effectiveness measures, and other general study settings across studies. Our analysis took the influence of such variability into account and found that most studies provided supportive evidence in terms of the cost-effectiveness of RDT.

However, there were still five studies that did not draw a clear conclusion \[[@CR28], [@CR33], [@CR34], [@CR36], [@CR38]\]. This difference can be explained by the accuracy of RDT, the performance of its comparisons, clinicians' compliance with the diagnostic results, total treatment costs, and malaria prevalence. Therefore, we were unable to conclude which strategy would be the most cost-effective with certainty.

A wide range of perspectives has been selected by the studies included. Although most of the studies under the societal and health sector perspectives supported the cost-effectiveness of RDT, some could not because of the uncertainty in the costs and an unclear WTP threshold. This might suggest that the diagnosis and treatment of malaria can be unaffordable to patients in many countries. The recommended first-line malaria treatment, artemisinin-based combination therapy (ACT), is expensive and possible increase in treatment costs over time due to therapy resistance and drug prices has been seldom considered by researchers in the field trials. A cost-effective intervention can be considered to receive public funding if it is a public good, or has important externalities and inadequate demand, or is catastrophically unaffordable and has no available insurance, or beneficiaries are poor when utility outcome is not available \[[@CR43]\]. Given the expensive treatment costs, it is suggested that malaria case management with RDT should be included in the coverage of health insurance to substantially reduce the economic burden on patients and their families \[[@CR44], [@CR45]\].

Another key driver for the cost-effectiveness of RDT is its price \[[@CR27], [@CR30], [@CR31], [@CR33], [@CR36], [@CR41]\]. The price of RDT can be determined by its type as combo RDTs are usually more costly than the single tests. In our analysis, it is uncertain whether the cost-effectiveness of RDT could be influenced by the types of RDT. Also, the capability of combo tests to identify plasmodium species can largely influence the cost-effectiveness of RDT because the type of RDT selected will determine not only the accuracy of diagnosis \[[@CR46]\], but also the following treatment received. Therefore, for most countries where multiple malaria species dominate, it is necessary to differentiate Plasmodium species such that proper treatment could be delivered.

This systematic review included studies from low- and middle-income countries that were assumed to be malaria endemic. The cost-effectiveness of RDT compared to microscopy was not clear in regions with relatively low transmission settings given the uncertainty in how the routine microscopy was performed, i.e., the accuracy of microscopy and whether the microscope was used only for malaria detection. Current evidence suggested that RDT could be more cost-effective than microscopy \[[@CR29], [@CR37], [@CR39], [@CR41]\], and the relative advantage of RDT could be further enhanced if microscope was exclusively-used \[[@CR37]\]. This could be explained by the fact that the demand for malaria diagnosis would be less in area where malaria prevalence is close to zero, and the cost per suspected patient would be largely increased when taking microscopy as the initial approach. Further studies are required to confirm this, especially in low transmission countries aiming at eliminating malaria.

Moreover, facing the reduction of malaria prevalence and movements towards disease elimination \[[@CR47]\], it is more common for countries to confront the threat of increasing malaria imported cases \[[@CR6]\]. Usually, imported patients are either rural migrant workers or travelers to the endemic region, and tend to have lower parasite densities. The key challenge is to promptly and accurately identify malaria cases at all levels of health systems. Current malaria control programs have established either active or passive case detection systems. Active case detection requires health workers to seek out for patients, making it less feasible to maintain the use of microscopy as the initial approach when the prevalence is extremely low. In addition to this, our requirements for malaria elimination, especially a consistent diagnostic accuracy for community-based primary care, is beyond the capacity of routine microscopy due to the scarcity of well-trained microscopists \[[@CR48]\], and essential laboratory supplies. This may limit the performance of microscopy \[[@CR49]\], and contribute to misdiagnosis or over-diagnosis with a potential risk of over-consuming antimalarial therapies and drug resistance \[[@CR50]\]. In fact, the poor performance of routine microscopy has been widely recognized, even in developed countries \[[@CR51]\], and high capital investment of microscopy makes it more costly than RDT if local caseload is low \[[@CR52]\]. Therefore, it is meaningful and economically important to introduce RDT in primary health care or remote region where microscopy is unavailable.

Quality of the evidence {#Sec22}
-----------------------

The CHEERS tool was used to assess the quality of evidence in our research, allowing to compare reporting quality across included studies. The majority of studies identified are of good and moderate quality, but we still found some studies showed poor compliance with the reporting guidance, especially lacking details of research methods. Explanation of model selection was lacked generally, and this might be because studies tended to have more concern about whether RDT was a quick and accurate way to detect malaria cases. It should also be noticed that the scores of studies aimed at measuring the cost-effectiveness of RDT were higher than those only evaluating the costs of the disease detection approaches.

In addition, the CHEERS tool focuses on the quality of reporting, and it should be fully considered at the stage of study design, for example, by referring to the structural abstract proposed by NHS Economic Evaluation Database (NHS EED) and extracting basic characteristics and results of health economic evaluations to improve the quality of evidence.

Limitations {#Sec23}
-----------

This review is limited in the following aspects: firstly, the studies identified were conducted in a limited range of countries, most of which were located in Africa. Whether results obtained from the context can be transferable to other countries was not elaborated in the included studies. It is obvious that countries may vary in their widely-used malaria diagnostic methods and other features such as prevalence and the types of RDT. Differences in health care systems and reimbursement also limit the transferability of our results. Thus, caution should be taken when applying the results to other settings. Another limitation was inadequate data on costs and effectiveness, possibly due to differences in adopting primary and secondary outcome indicators among studies, adding to the difficulty in comparing ICERs obtained when they had the same perspectives. Therefore, no synthesized outcome was shown due to the wide difference across studies and the lack of evidence regarding health utility gained when using different malaria diagnostic techniques. We suggest that further economic evaluations of malaria detection methods should focus on health utility benefits for patients who are susceptible to the disease.

Conclusions {#Sec24}
===========

We compared the cost-effectiveness of malaria RDT to other conventional diagnostic methods based on fifteen economic evaluations identified. However, there was high heterogeneity across economic evaluations identified in the outcome measures selection, the use of comparative diagnostic methods, and study settings. RDT was highly likely to be consistently cost-effective compared to presumptive diagnosis and routine microscopy, particularly in a low transmission setting. Further economic evaluations with better quality and comparable study designs were required.
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ACT

:   Artemisinin-based combination therapy

CHEERS

:   Consolidated Health Economic Evaluation Reporting Standards

PCR

:   Polymerase chain reaction
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:   Rapid diagnostic test
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